<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">Patients treated during the plerixafor showed a trend towards fewer apheresis sessions, lower total apheresis blood volume and less time spent on apheresis. These differences were not statistically significant (Table 
 <xref rid="Tab2" ref-type="table">2</xref>). A CD34+ collection yield of 2 × 10
 <sup>6</sup> cells/kg was achieved by 34 patients (83%) treated in the pre-plerixafor period and by 46 patients (90%) in the plerixafor era (
 <italic>p</italic> = 0.74). The costs associated with apheresis decreased from €5631 to €4765 (
 <italic>p</italic> = 0.07).
</p>
